NCT00044031已完成3 期
Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 394
- 主要终点
- Survival
研究概览
简要总结
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Survival
时间窗: Up to 12 months
次要结局
- Number of Participants with Serious and Non-Serious Adverse Events(Up to 12 months)
研究者
相似试验
已完成
2 期
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal CancerStomach NeoplasmsEsophageal NeoplasmsNCT00042510Cancer Advances Inc.103
已完成
不适用
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaLymphomaNCT00594815Memorial Sloan Kettering Cancer Center52
已完成
1 期
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsRecurrent Prostate CancerStage IV Prostate CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00058253National Cancer Institute (NCI)80
已完成
2 期
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant MelanomaMelanoma (Skin)NCT00104897Cancer Research UK25
进行中（未招募）
2 期
Cisplatin+Pembrolizumab+RT in Vulvar CancerVulvar Squamous Cell CarcinomaVulvar CancerNCT04430699Massachusetts General Hospital24